Assessment of low-dose ASA discontinuation risk associated with concomitant PPI use during the first year of ASA therapy

Study identifier:D5040N00008

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Assessment of low-dose ASA discontinuation risk associated with concomitant PPI use during the first year of ASA therapy for secondary prevention

Medical condition

Cardiovascular prevention

Phase

Healthy volunteers

Study drug

Risk of low dose aspirin discontinuation

Sex

All

Actual Enrollment

35604

Study type

Observational

Age

50 Years - 84 Years

Date

Study Start Date: 01 Sept 2012

Primary Completion Date: 01 Jun 2013

Study Completion Date: 01 Jun 2013

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Dec 2014 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Madrid, Spain

Arms	Assigned Interventions
Aspirin discontinuers; Aspirin non-discontinuers Patients on low dose ASA for secondary prevention that discontinue aspirin and those not discontinuing aspirin	Drug: Risk of low dose aspirin discontinuation PPI continuous use; No PPI usePPI
Drug PPI continuous use; No PPI use	-

"There is no result for the study"

Documents available

D5040N00008_CSP.pdf
Download
CSR Synopsis D5040N00008
Download
D5040N00008_Protocol
Download
Trial Results Summaries
Available here

Contacts

Investigators

Principal Investigator

Luis A Garcia Rodriguez

CEIFE (Centro Espanol de Investigacion Farmacoepidemiologica - Spanish Centre for Pharmacoepidemiologic Research )